Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Today Bahrain.
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
Press releases published on July 1, 2025
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
GlobeNewswire
·
July 1, 2025
REYKJAVIK, Iceland and LONDON, July 01, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz …
UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss
GlobeNewswire
·
July 1, 2025
Sheffield, July 01, 2025 (GLOBE NEWSWIRE) -- UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss Rincell-1 addresses a multi $Bn global market opportunity where no …
ONWARD Medical Files 510(k) with US FDA for ARC-EX System Home Use and Submits CE Mark Application
GlobeNewswire
·
July 1, 2025
FDA 510(k) application submitted to allow marketing of the ARC-EX® System for home use in the United States CE Mark application filed with notified body to enable commercialization of the ARC-EX System in the European Union and other countries EINDHOVEN, …
ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility
GlobeNewswire
·
July 1, 2025
RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low serum testosterone No FDA-approved oral therapies currently exist for this underserved population LAUSANNE, Switzerland and …
Poor mental health, police cuts fueled pandemic spike in impaired-driving deaths
GlobeNewswire
·
July 1, 2025
ARLINGTON, Va., July 01, 2025 (GLOBE NEWSWIRE) -- A national mental health crisis and reductions in policing may have helped fuel an increase in impaired-driving deaths during the COVID-19 pandemic, while the role of more liberal alcohol policies was …
Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants
GlobeNewswire
·
July 1, 2025
VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”) announces that it will apply to the TSX Venture Exchange (the “Exchange”) to amend the terms of certain outstanding warrants and …
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
GlobeNewswire
·
July 1, 2025
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of …
Public Pressure Mounts: Campaign Reaches 155,000 Families, Calls for Action to Solve Child Care Crisis
GlobeNewswire
·
July 1, 2025
OMAHA, Neb., June 30, 2025 (GLOBE NEWSWIRE) -- Amidst a child care crisis, We Care for Kids/Por todos los niños is marking three years of spreading awareness about the importance of quality and affordable child care through its statewide public education …
Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
GlobeNewswire
·
July 1, 2025
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required …